← back to search

R. Jeffrey Karnes

Mayo Clinic · US
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Bladder and Urothelial Cancer Treatments, and Urinary and Genital Oncology Studies.
h-index
86
citations
24,762
works
1,128
NIH funding
primary concept
Medicine
email

Recent publications

Prostate Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network 2024cited by 258position: middledoi
Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted Prostate Biopsy: A Systematic Review and Meta-analysis of Prospective Studies
European Urology Oncology 2024cited by 39position: middledoi
Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer
European Urology 2024cited by 12position: middledoi
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes
Cancer 2023cited by 34position: middledoi
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets
Nature Communications 2022cited by 148position: middledoi
Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer
JAMA Oncology 2022cited by 45position: middledoi
Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race
European Urology Open Science 2022cited by 12position: middledoi
SPOP mutation induces DNA methylation via stabilizing GLP/G9a
Nature Communications 2021cited by 69position: middledoi
Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer
Journal of Clinical Investigation 2021cited by 39position: middledoi
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer
JAMA Network Open 2021cited by 33position: middledoi
Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features
JAMA Network Open 2021cited by 30position: middledoi
Genetic factors associated with prostate cancer conversion from active surveillance to treatment
Human Genetics and Genomics Advances 2021cited by 23position: middledoi
MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression
Cancer Research 2021cited by 23position: middledoi
Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer
European Urology 2021cited by 18position: middledoi
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
Journal of Clinical Oncology 2020cited by 277position: middledoi
A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer
European Urology 2020cited by 205position: middledoi
Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic
European Urology 2020cited by 140position: middledoi
NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer
International Journal of Radiation Oncology*Biology*Physics 2020cited by 138position: middledoi
Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought
European Urology 2020cited by 111position: middledoi
Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate
JAMA Oncology 2020cited by 90position: middledoi
Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer
Clinical Cancer Research 2020cited by 90position: middledoi
A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance
Nature Cancer 2020cited by 82position: middledoi
Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of <sup>68</sup> Ga-PSMA and <sup>11</sup> C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections
The Journal of Urology 2020cited by 38position: middledoi
Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier
Prostate Cancer and Prostatic Diseases 2020cited by 26position: middledoi
Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy
European Urology Oncology 2020cited by 24position: middledoi
High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program
Nature Communications 2019cited by 180position: middledoi
Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches
The Journal of Urology 2019cited by 90position: middledoi
Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer
European Urology Focus 2019cited by 63position: lastdoi
Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review
World Journal of Urology 2019cited by 29position: middledoi
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target
JNCI Journal of the National Cancer Institute 2018cited by 209position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Elai Davicioni · Coherus BioSciences (United States)19 papers (2013–2023)Steven Joniau · AZ Sint-Blasius12 papers (2012–2018)Alberto Briganti · Collaborative Group (United States)12 papers (2012–2024)Edward M. Schaeffer · Northwestern University11 papers (2013–2023)Nicholas Erho · NewYork–Presbyterian Hospital11 papers (2013–2018)Giorgio Gandaglia · Vita-Salute San Raffaele University10 papers (2013–2024)Robert B. Den · Thomas Jefferson University10 papers (2015–2023)Francesco Montorsi · Atlanta VA Medical Center10 papers (2012–2018)Shahrokh F. Shariat · University Hospital in Motol9 papers (2012–2024)Ashley E. Ross · Northwestern University9 papers (2013–2021)Felix Y. Feng · Polytechnique Montréal8 papers (2013–2021)Daniel E. Spratt · Drexel University7 papers (2016–2023)Eric A. Klein · ATUM (United States)7 papers (2015–2022)Haojie Huang · Indiana University School of Medicine7 papers (2015–2021)Markus Graefen · Eppendorf (Germany)6 papers (2012–2017)Paolo Gontero · Ospedale San Luigi Gonzaga6 papers (2012–2019)Mohammed Alshalalfa · University of California, San Francisco6 papers (2015–2021)Stephen J. Freedland · Cedars-Sinai Medical Center6 papers (2016–2022)Robert B. Jenkins · Mayo Clinic6 papers (2013–2017)Stephen A. Boorjian · Mayo Clinic5 papers (2013–2017)